The occurrence of BC in FtM transgenders depends on the completeness of removing all mammary tissue by mastectomy [70, 72, 74] and is comparable to the prevention of BC by mastectomy in high-risk women carrying germline mutations such as BRCA1 and BRCA2 [75]. This evidence concerns the gene BRCA2 and breast cancer.